CCR3

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

Retrieved on: 
Thursday, November 16, 2023
Fibroblast, Parallel Walk Test, Endothelium, Therapy, Pathology, Scleroderma, Systemic scleroderma, CMMB, Axis, Risk, Pulmonary hypertension, Patient, Nature, American College of Rheumatology, Autoimmune disease, Orthostatic hypertension, American College, CCR3, Malignancy, CCL24, Sclerosis, Communication, Doctor of Philosophy, PAH, Skin, ACR, TEL, Pharmaceutical industry, Disease

TEL AVIV, Israel, Nov. 16, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today reported on its poster presentation at the American College of Rheumatology (ACR) Convergence 2023 conference. The study, which was conducted by Chemomab researchers working in collaboration with academic scientists, analyzed serum samples and clinical data from patients with systemic sclerosis (SSc) to assess the effect of the soluble protein CCL24 on the pathogenesis of SSc and its association with key aspects of SSc pathology. Chemomab's first-in-class monoclonal antibody, CM-101, is designed to neutralize CCL24 and normalize CCL24-driven fibro-inflammatory disease processes. CM-101 has been studied extensively in preclinical and patient models of SSc. Chemomab has an open IND in the U.S. for a Phase 2 trial of CM-101 in systemic sclerosis patients.

Key Points: 
  • Chemomab's first-in-class monoclonal antibody, CM-101, is designed to neutralize CCL24 and normalize CCL24-driven fibro-inflammatory disease processes.
  • Chemomab has an open IND in the U.S. for a Phase 2 trial of CM-101 in systemic sclerosis patients.
  • Systemic sclerosis is an autoimmune disease characterized by vascular injury and extensive tissue fibrosis of the skin and internal organs.
  • Using cell-based assays, the researchers showed that CCL24, alongside factors present in the SSc microenvironment, enhances the EndMT process.

Chemomab Presents Preclinical Data at AASLD The Liver Meeting® 2022 Highlighting Key Role of CCL24 in Pathophysiology of Primary Sclerosing Cholangitis

Retrieved on: 
Monday, November 7, 2022
Doctor of Philosophy, RNA, Private Securities Litigation Reform Act, Flow cytometry, Therapy, Research, Risk, Serum, Liver, D.C, CCL24, CMMB, TEL, B cell, Fibrosis, Scar, Non-alcoholic fatty liver disease, American Association for the Study of Liver Diseases, CCL11, Institute of Liver and Biliary Sciences, Nasdaq, AASLD, Primary sclerosing cholangitis, Marketing, Nature, Inflammation, CCR3, Cirrhosis, PSC, Macrophage, Liver disease, CSO, Forward-looking statement, Neutrophil, ALP, Disease, R, Monocyte, SEC, Association, Patient, American Association, Communication, Pharmaceutical industry, Vaccine

TEL AVIV, Israel, Nov. 7, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced a poster presentation at The Liver Meeting® 2022, hosted by the American Association for the Study of Liver Diseases (AASLD), being held in Washington, D.C. November 4-8, 2022.

Key Points: 
  • Chemomab is currently assessing CM-101 in a Phase 2 clinical trial for the treatment of PSC.
  • Chemomab researchers used flow cytometry and single-cell RNA sequencing (scRNA-seq) methods to analyze immune cell trafficking in an animal model of PSC.
  • Furthermore, the studies showed that these effects are distinctive to CCL24 compared to CCL11, a member of a related pro-inflammatory cytokine family.
  • The Liver Meeting 2022 hosted by AASLD is the world's premier meeting on liver disease providing access to the most cutting-edge science in the field.

Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

Retrieved on: 
Friday, July 22, 2022
Revelation, GLOBE, Allergic rhinitis, Immunity, Degenerative disease, Trial of the century, Forward-looking statement, SAN, SEC, EMA, Private Securities Litigation Reform Act, Basophil, Risk, Safety, COVID-19, NASDAQ, Pollen, T helper cell, Disease, FDA, SPAC, Vaccination, CCR3, Eosinophil, Pharmaceutical industry, Vaccine

This includes no reduction in allergy symptoms (Total Nasal Symptom Score) and no increase in peak nasal inspiratory flow versus placebo.

Key Points: 
  • This includes no reduction in allergy symptoms (Total Nasal Symptom Score) and no increase in peak nasal inspiratory flow versus placebo.
  • The study enrolled two cohorts: one cohort received study drug prior to nasal allergen challenge (the prophylactic cohort) and the second cohort received study drug after the nasal allergen challenge (the treatment cohort).
  • The Phase 1b, randomized, double-blind, placebo-controlled, crossover study design was conducted in Australia.
  • Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease.

Revelation Biosciences Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

Retrieved on: 
Thursday, July 14, 2022
People, Allergic rhinitis, Disease, Allergen, Eosinophil, SEC, Safety, Basophil, SPAC, NASDAQ, Nasal congestion, Vaccination, Immunity, Sneeze, T helper cell, Risk, Mouth, EMA, Patient, SAN, Allergy, GLOBE, Atmosphere, COVID-19, Media, Degenerative disease, Sinusitis, Private Securities Litigation Reform Act, Nose, Trial of the century, Polyp (medicine), Forward-looking statement, CCR3, FDA, Quality of life, Pollen, Revelation, Pharmaceutical industry, Online shopping, Vaccine

Key exploratory endpoints include allergy symptoms (Total Nasal Symptom Score) and peak nasal inspiratory flow elicited by nasal allergen challenge.

Key Points: 
  • Key exploratory endpoints include allergy symptoms (Total Nasal Symptom Score) and peak nasal inspiratory flow elicited by nasal allergen challenge.
  • Allergic rhinitis, or hay fever, is an allergic reaction to tiny particles in the air called allergens.
  • Allergic rhinitis can lead to complications in some cases including nasal polyps, sinusitis, and middle ear infections.
  • REVTx-99b, the lead therapeutic candidate, is being developed for allergic rhinitis, and is currently being evaluated as a treatment for allergic rhinitis in a Phase 1b CLEAR study.

Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis 

Retrieved on: 
Monday, June 13, 2022
People, Vaccination, Allergic rhinitis, Nasal congestion, Eosinophil, Allergen, EMA, Nose, Forward-looking statement, Immunity, Disease, Sneeze, SPAC, Allergy, Revelation, Degenerative disease, Basophil, FDA, Media, Polyp (medicine), GLOBE, Patient, Private Securities Litigation Reform Act, Risk, Trial of the century, COVID-19, Atmosphere, Quality of life, NASDAQ, SEC, T helper cell, SAN, Sinusitis, CCR3, Safety, Pharmaceutical industry, Online shopping, Vaccine

Allergic rhinitis, or hay fever, is an allergic reaction to tiny particles in the air called allergens.

Key Points: 
  • Allergic rhinitis, or hay fever, is an allergic reaction to tiny particles in the air called allergens.
  • Allergic rhinitis can lead to complications in some cases including nasal polyps, sinusitis, and middle ear infections.
  • Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease.
  • REVTx-99b, the lead therapeutic candidate, is being developed for allergic rhinitis, and is currently being evaluated as a treatment for allergic rhinitis in a Phase 1b CLEAR study.

Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis

Retrieved on: 
Monday, May 23, 2022
People, Risk, Disease, Allergy, Polyp (medicine), Sneeze, Private Securities Litigation Reform Act, Polyp, Degenerative disease, CCR3, Patient, Revelation, NASDAQ, Quality of life, Sinusitis, COVID-19, Trial of the century, Vaccination, FDA, SAN, Media, Nasal congestion, SMC, Allergic rhinitis, Atmosphere, EMA, Immunity, SPAC, Forward-looking statement, Safety, T helper cell, Eosinophil, Nose, Mouth, SEC, Allergen, Network congestion, GLOBE, Pharmaceutical industry, Online shopping, Vaccine

The primary endpoint is to evaluate the effects of REVTx-99b versus placebo on safety and tolerability.

Key Points: 
  • The primary endpoint is to evaluate the effects of REVTx-99b versus placebo on safety and tolerability.
  • Key secondary endpoints include allergy symptoms (Total Nasal Symptom Score) and peak nasal inspiratory flow elicited by nasal allergen challenge.
  • Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease.
  • REVTx-99b, the lead therapeutic candidate, is being developed for allergic rhinitis, and is currently being evaluated as a treatment for allergic rhinitis in a Phase 1b CLEAR study.

Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza Infection

Retrieved on: 
Wednesday, March 30, 2022
Private Securities Litigation Reform Act, Degenerative disease, Risk, Eosinophil, NASDAQ, Vaccination, T helper cell, Trial of the century, Forward-looking statement, SPAC, SEC, Viral load, Immunity, Safety, COVID-19, GLOBE, EMA, CCR3, AUC, Allergic rhinitis, SAN, FDA, Patient, Disease, Revelation, Pharmaceutical industry, Vaccine, Online shopping

Revelation is currently in a Phase 1b, randomized, double-blind, placebo-controlled, crossover design study.

Key Points: 
  • Revelation is currently in a Phase 1b, randomized, double-blind, placebo-controlled, crossover design study.
  • Key secondary endpoints include allergy symptoms (Total Nasal Symptom Score) and peak nasal inspiratory flow elicited by nasal allergen challenge.
  • Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease.
  • Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made.

Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention of H3N2 Influenza Infection

Retrieved on: 
Thursday, March 24, 2022
Private Securities Litigation Reform Act, Degenerative disease, Risk, Eosinophil, NASDAQ, T helper cell, Vaccination, Influenza, Trial of the century, Respiratory syncytial virus, Forward-looking statement, SEC, Viral load, Interferon, Incidence, MMID, Rhinovirus, Data analysis, Severe acute respiratory syndrome coronavirus 2, Immunity, TLR4, Technology, COVID-19, RT, GLOBE, RSV, EMA, Infection, AUC, CCR3, Allergic rhinitis, Immunization, SAN, FDA, Seroconversion, Disease, Revelation, Pharmaceutical industry, Vaccine

SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, outlines details on the upcoming data analysis for Phase 2b viral challenge study (RVL-VRL01) to evaluate the efficacy of intranasal REVTx-99a for the preventive treatment of H3N2 influenza (influenza A) infection in healthy humans. Dosing and enrollment for this study were recently completed and primary endpoint analysis is expected early Q2 2022, followed by final data analysis in Q2 2022.

Key Points: 
  • Dosing and enrollment for this study were recently completed and primary endpoint analysis is expected early Q2 2022, followed by final data analysis in Q2 2022.
  • The Phase 2b, randomized, double-blind, placebo-controlled study was conducted in Belgium and enrolled healthy individuals 18 to 55 years of age.
  • Generally, the higher the amount of virus (viral load), the more infected, and by conjunction, the sicker a person may be.
  • The viral challenge study is the next necessary step in clinical development of REVTx-99a for the treatment of respiratory viral infections.

Revelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99 for the Prevention of H3N2 Influenza Infection

Retrieved on: 
Tuesday, March 15, 2022
Viral load, SEC, Trial of the century, Influenza, Degenerative disease, Technology, GLOBE, Polyp, RSV, Immunity, Allergic rhinitis, Private Securities Litigation Reform Act, FDA, T helper cell, Risk, COVID-19, Infection, EMA, Eosinophil, Forward-looking statement, AUC, NASDAQ, TLR4, CCR3, Respiratory syncytial virus, Seroconversion, Incidence, Severe acute respiratory syndrome coronavirus 2, Interferon, Revelation, MMID, SAN, Rhinovirus, Vaccination, Disease, Vaccine, Pharmaceutical industry

SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today that it has completed enrollment and dosing in Phase 2b viral challenge study (RVL-VRL01) to evaluate the efficacy of intranasal REVTx-99 for the preventive treatment of H3N2 influenza (influenza A) infection in healthy humans.

Key Points: 
  • The viral challenge study is the next necessary step in clinical development of REVTx-99 for the treatment of respiratory viral infections.
  • The Phase 2b, randomized, double-blind, placebo-controlled study was conducted in Belgium and enrolled healthy individuals 18 to 55 years of age.
  • Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease.
  • REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity.

Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza Infection

Retrieved on: 
Thursday, January 20, 2022
Vaccination, Forward-looking statement, Patient, Technology, Degenerative disease, SAN, Vaccine, Allergic rhinitis, Incidence, Private Securities Litigation Reform Act, EMA, SEC, COVID-19, RSV, Severe acute respiratory syndrome coronavirus 2, CCR3, TLR4, Influenza, Seroconversion, Safety, NASDAQ, Disease, Respiratory syncytial virus, GLOBE, T helper cell, Interferon, AUC, Infection, Viral load, Immunity, MMID, Rhinovirus, Risk, Eosinophil, Revelation, FDA, Polyp, Online shopping

The viral challenge study is the next necessary step in clinical development of REVTx-99 for the treatment of respiratory viral infections.

Key Points: 
  • The viral challenge study is the next necessary step in clinical development of REVTx-99 for the treatment of respiratory viral infections.
  • With respiratory viral infections like influenza, COVID-19, and its emerging variants there is a huge need for new therapies, said James Rolke, Chief Executive Officer of Revelation.
  • Despite having vaccines, there remains an urgent need for multiple therapeutic approaches to help prevent and treat respiratory viral infections.
  • The Phase 2b, randomized, double-blind, placebo-controlled study will enroll up to 60 participants (four groups of 15 patients).